by David Brindley | Jul 9, 2013
. At the close of ISSCR2013, I left Boston bathed in an ochre sunset, and settled on a plane to reflect on what my most unexpected learning had been. My plane was bound not for home (London), but for Istanbul, where the TERMIS meeting was about to begin. As far as I’m...
by Paul Krzyzanowski | Jun 6, 2013
GMO soybeans might have lessons for cell patents. Photo: Philip Dean via Flickr . At first glance, you wouldn’t think that a 76-year old soybean farmer from Indiana would have something in common with microbiologists, but Vernon Hugh Bowman brought back memories of my...
by Paul Krzyzanowski | Apr 16, 2013
. Last week I posted a summary of the first half of a full day Communications for Scientists workshop organized by the Stem Cell Network. This post picks up where I left off, with a description of a “Dragon’s Den” style pitch session intended to introduce trainees to...
by Paul Krzyzanowski | Mar 13, 2013
[pullquote]In time, this purchase might make BioTime the company that Geron was supposed to be.[/pullquote]Avid watchers of the stem cell and regenerative medicine market have no doubt heard of Geron selling its stem cell assets to BioTime. Nature covered it in some...
by Natasha Davie | Mar 5, 2013
When it comes to the cell therapy commercialization crunch there are some fundamental questions that need to be answered. Is your product going to be frozen or fresh? How will the product be administered? What is your dosing strategy? And the one that I’m going to...
by David Brindley | Jan 16, 2013
claimtoken-510012802486f [pullquote]The cell therapy industry has an encyclopaedic void. But is this void one that needs addressing?”[/pullquote]This post was initially intended to be a short vignette (not so short, as it turns out) exploring whether or not the...
Comments